Zoladex 3-Month Depot Implant Is Approved
WILMINGTON, Del--Zeneca Pharmaceuticals has received clearance from the FDA to market a new formulation of Zoladex (goserelin acetate implant) for the palliative treatment of advanced prostate cancer.
WILMINGTON, Del--Zeneca Pharmaceuticals has received clearancefrom the FDA to market a new formulation of Zoladex (goserelinacetate implant) for the palliative treatment of advanced prostatecancer.
The new formulation, a 10.8-mg goserelin acetate implant givenevery 3 months, offers greater convenience to patients choosingtreatment with a luteinizing-hormone-releasing hormone (LHRH)analog, the company said.
The original 1-month 3.6-mg formulation of Zoladex implants hasbeen available in the United States since 1989 for the treatmentof advanced prostate cancer. The drug has been marketed since1993 for the treatment of endometriosis, and it was recently clearedby the FDA for the treatment of advanced breast cancer in premenopausaland perimeno-pausal women.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
